l e t t e r s
Genome-wide association studies have recently identified at least 15 susceptibility loci for systemic lupus erythematosus (SLE). To confirm additional risk loci, we selected SNPs from 2,466 regions that showed nominal evidence of association to SLE (P < 0.05) in a genome-wide study and genotyped them in an independent sample of 1,963 cases and 4,329 controls. This replication effort identified five new SLE susceptibility loci (P < 5 × 10 −8 ): TNIP1 (odds ratio (OR) = 1.27), PRDM1 (OR = 1.20), JAZF1 (OR = 1.20), UHRF1BP1 (OR = 1.17) and IL10 (OR = 1.19). We identified 21 additional candidate loci with P ≤ 1 × 10 −5 . A candidate screen of alleles previously associated with other autoimmune diseases suggested five loci (P < 1 × 10 −3 ) that may contribute to SLE: IFIH1, CFB, CLEC16A, IL12B and SH2B3. These results expand the number of confirmed and candidate SLE susceptibility loci and implicate several key immunologic pathways in SLE pathogenesis.
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease characterized by the presence of antibodies to nuclear self-antigens. Many of the lupus autoantibodies recognize nucleic acids and nucleic acid binding proteins, which in turn activate Toll-like receptors, leading to the production of type I interferon 1 . Despite considerable clinical heterogeneity, SLE ranks among the most heritable of common autoimmune diseases, with a sibling risk ratio of ~30 (ref. 2) . Recent genome-wide association (GWA) and candidate gene studies have identified at least 15 common SLE risk alleles that achieve genome-wide significance (P < 5 × 10 −8 ). These include genes encoding proteins important for adaptive immunity and the production of autoantibodies (HLA class II alleles, BLK, PTPN22 and BANK1) and proteins with roles in innate immunity and interferon signaling (ITGAM, TNFAIP3, STAT4 and IRF5) [3] [4] [5] [6] [7] [8] [9] [10] . To identify additional risk loci, we performed a targeted replication study of SNPs from 2,466 loci that showed a nominal P value of <0.05 in a recent GWA 7 scan of 1,310 individuals with lupus (cases) and 7,859 controls. We also genotyped SNPs from 23 previously reported SLE risk loci, 42 SNPs implicated in other autoimmune diseases and over 7,000 ancestry-informative markers (Fig. 1) .
We designed a custom SNP array (Illumina Infinium II) consisting of over 12,000 variants and genotyped two independent SLE case and control populations from the United States (1,129 SLE cases and 2,991 controls) and Sweden (834 SLE cases and 1,338 controls). Included among the US controls were 2,215 Alzheimer's disease case-control samples, which were judged to be acceptable as controls because the genetic factors underlying SLE and Alzheimer's disease are expected to be independent. We next applied data quality filters to remove poorly performing samples and SNPs, population outliers, duplicate samples and related individuals (see Online Methods). Following these quality l e t t e r s control measures, we examined a final set of 10,848 SNPs (Fig. 1) . Association statistics for 3,735 SNPs were calculated and corrected for population stratification using 7,113 ancestry-informative markers (see Online Methods).
We first examined 25 SNPs (from 23 loci) that were previously reported to be associated with SLE ( Table 1 and Supplementary  Table 1) . We found further evidence of association for 21 of the variants (P < 0.05), including 9 loci that reached genome-wide significance (P < 5 × 10 −8 ) in the current combined dataset. Figure 1 Overview of experimental design. Variants were selected from loci with P < 0.05 in a genome-wide scan of 1,310 cases and 7,859 controls, previously reported SLE risk loci, confirmed loci from other autoimmune diseases and over 7,000 ancestry-informative markers, and these variants were incorporated into an Illumina custom SNP array. The array was genotyped in independent cases and controls from the United States and Sweden. 823 of the Swedish controls were genotyped using the Illumina 310K SNP array. Variants were analyzed as described in Online Methods. 9 identified MECP2 as a potential risk locus for SLE; however, in the current dataset, SNPs near IRAK1, a gene critical for Toll-like receptor 7 and 9 signaling and located within the identified region of linkage disequilibrium (LD) surrounding MECP2, showed the strongest evidence of association. Similar findings were recently reported 11 , and further work will be required to determine the causal allele in the IRAK1-MECP2 locus. We found additional evidence of association for three loci (TYK2, ICA1 and NMNAT2) that had previously shown significant but not genome wide-level evidence for association 6, 10 . For four previously implicated variants (LYN, SCUBE1, TLR5 and LY9), no evidence of association was observed in the combined dataset.
To identify previously unknown SLE risk loci, we examined 3,188 SNPs from 2,446 distinct loci that showed evidence of association to SLE in our genome-wide dataset 7 , which comprised 502,033 SNPs genotyped in 1,310 SLE cases and an expanded set of 7,859 controls. Using this dataset, we imputed over 2.1 million variants using Phase II HapMap CEU samples as a reference (see Online Methods) and generated a rank-ordered list of association statistics. Variants with P < 0.05 were selected for possible inclusion on the custom replication array. For efficient genotyping, we identified groups of correlated variants (r 2 > 0.2) and then carried out selection of at least two SNPs from each group where all SNPs had P < 0.001. For the remaining groups, the SNP with the lowest P value in the group was included. In the replication samples, we calculated the association statistics (see Online Methods) and observed a significant enrichment of the replication results relative to the expected null distribution (Fig. 2) . Excluding previously reported SLE risk alleles, there were 134 loci with P < 0.05 (64 expected; P = 2 × 10 −15 ) and 12 loci with P < 0.001 (1 expected; P = 1 × 10 −9 ), suggesting the presence of true positive associations.
The replication study identified five new SLE risk loci with a combined P value that exceeded the genome-wide threshold for significance (P < 5 × 10 −8 ): TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 ( Table 2 and Supplementary Table 2 ). These loci are discussed in more detail below.
A variant (rs7708392) on 5q33.1 that resides within an intron of TNIP1 (encoding TNF-α-induced protein 3 (TNFAIP3)-interacting protein 1) was significantly associated with SLE in all three cohorts and had a combined P = 3.8 × 10 −13 ( Fig. 2) . Variants near TNIP1 were recently found to contribute to risk of psoriasis 12 ; however, the SLE and psoriasis risk variants are separated by 21 kb and appear to have distinct genetic signals (r 2 = 0.001). TNIP1 and TNFAIP3 are interacting proteins 13 , but the precise role of TNIP1 in regulating TNFAIP3 is unknown. The association of multiple distinct variants near TNFAIP3 with SLE 4,14 , rheumatoid arthritis 15 , psoriasis 12 and type 1 diabetes 16 suggests that this pathway has an important role in regulating autoimmunity. 
A second confirmed risk variant (rs6568431, P = 7.12 × 10 −10 ) was identified in an intergenic region between PRDM1 (PR domain containing 1, with ZNF domain, also known as BLIMP1) and ATG5 (APG5 autophagy 5-like). The signal at rs6568431 appears to be distinct from the previously reported 6 SLE risk allele within ATG5 (rs2245214 , Table 1) , as rs6568431 has an r 2 < 0.1 with rs2245214, and rs2245214 remains significantly associated with SLE (P < 1 × 10 −5 ) after conditional logistic regression incorporating rs6568431 (Fig. 2) .
The promoter region of JAZF1 (juxtaposed with another zinc finger gene 1) is a third newly confirmed SLE locus (rs849142, P = 1.54 × 10 −9 ). Of note, this same variant was previously associated with risk of type 2 diabetes 17 and with height variation 18 . A separate prostate cancer risk allele near JAZF1 (rs10486567) 19 showed no evidence for association in the current study.
A fourth newly identified SLE risk locus is defined by a nonsynonymous allele (R454Q) of UHRF1BP1 (ICBP90 binding protein 1; rs11755393, P = 2.22 × 10 −8 ). This allele encodes a nonconservative amino-acid change in a putative binding partner of UHRF1, a transcription and methylation factor linked to multiple pathways 20 . The UHRF1BP1 risk allele is in a region of extended LD that encompasses multiple genes, including SNRPC (small nuclear ribonucleoprotein polypeptide C), which is part of a RNA processing complex often targeted by SLE autoantibodies.
The fifth newly identified SLE locus is IL10 (interleukin-10; rs3024505, P = 3.95 × 10 −8 ; Fig. 2) . IL10 is an important immunoregulatory cytokine that functions to downregulate immune responses 21 , and variation in IL10 has inconsistently been reported to be associated with SLE 22 . The variant associated with SLE is identical to a SNP recently identified as contributing to risk of ulcerative colitis 23 and type 1 diabetes 24 , suggesting the possibility of shared pathophysiology in the IL10 pathway across these disorders.
Using a significance threshold of P < 1 × 10 −5 in the combined replication sample, we identified 21 additional SLE candidate risk loci ( Table 2 and Supplementary Table 2 ). Less than one locus (0.01 loci, specifically) with P < 1 × 10 −5 was expected under a null distribution for the meta-analysis (P = 8 × 10 −77 ), suggesting that several of these loci are likely to be true positives for association to SLE. Notable candidate genes in this list include: (i) IRF8 (interferon regulatory factor 8), which was implicated in a previous GWA study (GWAS) 4 and whose family members IRF5 and IRF7 are within confirmed SLE risk loci; (ii) TAOK3 (TAO kinase 3), a kinase expressed in lymphocytes, and the disease-associated variant is a missense allele (rs428073,N47S); (iii) LYST (lysosomal trafficking regulator), mutations of which cause Chediak-Higashi syndrome in humans, a complex disorder characterized by a lymphoproliferative disorder; and (iv) IL12RB2 (interleukin 12 receptor, beta 2), a locus which includes IL23R and SERPBP1 but 25 .
A noteworthy feature of recent GWAS is the large number of overlapping loci found to be shared between different complex diseases 26 . We tested 42 variants from 35 loci that were previously reported as autoimmune-disease risk alleles for association with SLE ( Table 3 and  Supplementary Table 3 ). No single locus had an unadjusted P value < 5 × 10 −8 ; however, we found an enrichment of previously identified disease-associated alleles. From the 35 loci tested (42 total variants), there were 5 alleles with unadjusted P < 0.0004 (less than 1 expected by chance, P = 4.4 × 10 −12 ) and with P < 0.05 after a Bonferroni correction for the 35 pre-specified loci. For each of the five variants, the SLE-associated allele matched a previously reported allele and had the same direction of effect ( Table 3) . We observed a highly significant association to SLE of a missense allele of IFIH1 (rs1990760, P = 3.3 × 10 −7 ) that has previously been associated with type 1 diabetes and Graves' disease 27, 28 . We also observed an association of SLE with a missense allele (R32Q) of CFB (complement factor B, rs641153) that resides in the HLA class III region and is a validated risk allele for age-related macular degeneration 29 . This missense allele in CFB is not in significant LD with other HLA region variants associated with SLE (DR2/DR3) and remained significant (P < 0.05) after conditional logistic regression analyses that incorporated DR2 and DR3. The HLA is a complex genetic region, but it is noteworthy that the rs641153 SNP has a protective effect nearly identical to that of the reported agerelated macular degeneration (AMD) risk allele 29 . Further validation of the five candidate disease alleles is required.
Using 26 SLE risk alleles (21 previously reported loci in Table 1 plus the 5 newly identified SLE loci), we performed several additional analyses. First, we performed pairwise interaction analysis with the previously confirmed loci, and, consistent with previous literature from SLE 6 and other complex diseases 30 , we observed no evidence for non-additive interactions. Using conditional logistic regression analyses, we found no evidence for multiple independent alleles contributing to risk at any of the individual risk loci. We next estimated the percent of variance explained by each of the confirmed SLE risk alleles using previously described methods 30 . HLA-DRB1 (HLA*DR3), IRF5 and STAT4 were each estimated to account for over 1% of the genetic variance, whereas the remaining loci each accounted for less than 1% of the variance. Together, the 26 SLE risk loci explain an estimated 8% of the total genetic susceptibility to SLE.
Targeted replication of GWAS results is an efficient study design to confirm additional risk loci 31 . However, there are few available data as to the probability of replicating results that fall short of accepted P value criteria for genome-wide significance. In the current study, all variants with P < 0.05 from the original GWAS were included for replication. The lower a locus' P value is in the GWAS, the higher is the probability of that locus reaching candidate or confirmed status in the replication meta-analysis (Fig. 3) . Of note, no candidate or confirmed loci were obtained in the current study from the group of variants with a GWAS P value between 0.05 and 0.01, despite accounting for ~50% of all variants tested in the replication. These results may be useful in helping guide future targeted study designs, although clearly the size of the original GWAS population, the replication sample size, the disease architecture and the effect size of the candidate disease-associated variants need to be carefully considered in planning replication efforts.
These data provide further evidence that common variation in genes that function in the adaptive and innate arms of the immune system are important in establishing SLE risk. Although each of the identified alleles accounts for only a fraction of the overall genetic risk, these and other ongoing studies are providing new insight into the pathogenesis of lupus and are suggesting new targets and pathways for drug discovery and development.
METhOdS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. All alleles in the table either were identical to the reported variants or have r 2 > 0.8 to the reported variant and were the same risk allele with the same direction of effect. Samples, individual and combined P values, risk allele frequency and OR are as described in table 1 legend. Combined-corrected P value is the Bonferroni-corrected P value for the 35 previously reported risk loci. Other autoimmunity associations: T1D, type 1 diabetes; AMD, age-related macular degeneration; MS, multiple sclerosis; IBD, inflammatory bowel disease. See supplementary table 3 for expanded summary statistics and a complete list of variants tested.
a Indicates markers that were imputed, as described in Online Methods, from the GWAS samples and directly genotyped in the replication samples. 
Percentage of variants with

Figure 3
Percentage of newly discovered variants reaching candidate (P < 1 × 10 −5 ) and confirmed (P < 5 × 10 −8 ) status in the meta-analysis stratified by the P value in the original GWAS.
ONLINE METhOdS
Subjects. Samples used in the GWA scan were as described 7 . In addition to the original 3,583 controls 7 , 4,564 controls from the Cancer Genetics Markers of Susceptibility (CGEMS) project were included after obtaining approval. The replication samples consisted of subjects from the United States and Sweden. The US subjects consisted of 1,129 individuals with SLE (cases) and 776 healthy controls from the New York Health Project collection 38 and a total of 2,215 Alzheimer's disease cases and healthy controls from the National Cell Repository for Alzheimer's Disease and collected at the University of Pittsburgh Medical Center (see Supplementary Table 4 ). In addition, samples from 888 Swedish SLE cases and 1,642 healthy Swedish controls were included. The case samples were collected from rheumatology clinics at the Uppsala, Lund, Karolinska (Solna) and Umeå University Hospitals. Controls were matched for age and gender and consisted of healthy blood donors (Uppsala, Lund) and controls from the population-based Epidemiological Investigation of Rheumatoid Arthritis cohort 39 . All cases were self-described individuals of European descent and had medical records documenting fulfillment of four or more of the American College of Rheumatology defined criteria for a positive diagnosis of SLE 40 . The studies were approved by the ethical committees of all institutions listed above, and all subjects gave informed consent.
Custom SNP array. An Illumina custom array with 10,848 SNPs that passed the quality control measured described below (12, 864 SNPs on the complete array) was designed and consisted of 3,188 SNPs selected based on a nominal P < 0.05 in an SLE genome-wide association scan, 505 SNPs from 25 previously reported SLE risk loci, 42 SNPs selected after a literature search for confirmed risk alleles from other autoimmune diseases, and 7,113 SNPs used for ascertaining and for controlling for population substructure. The latter group included SNPs that have been used to define continental population differences 41 and SNPs enriched for European population substructure 42 .
Quality control and imputation. US data. 1,464 cases and 3,078 controls were genotyped on the custom 12K chip. We used stringent quality control criteria to ensure that high-quality data were included in the final analysis. Specifically, we excluded 116 individuals who had >5% missing data and 279 individuals based on cryptic relatedness and duplicate samples based on identity-by-state status (PI_Hat > 0.15). We included only SNPs with <5% missing data, HardyWeinberg equilibrium P value > 1 × 10 −6 , minor allele frequency > 0.01% and P > 1 × 10 −5 in a test for differential missingness between cases and controls. SNPs were also examined for batch effects. After applying the above filters, 1,144 cases and 3,003 controls and 11,024 SNPs were available for analysis. All quality control tests were performed using PLINK 43 . Swedish data. A set of 888 cases and 527 controls genotyped on the custom 12K chip was available for analysis. A separate set of 1,115 Swedish controls genotyped on the 317K Illumina chip was also incorporated into the analysis. We used the following steps to combine the two datasets. First, an overlapping set of 6,789 SNPs between the 12K and 317K data was created. We used this set to examine the Swedish replication cohort for cryptic relatedness and duplicate samples. As a result, 313 samples were excluded (PI_Hat > 0.15). After quality control checks, we forwarded for analysis 863 cases and 523 controls genotyped on the custom 12K chip and 831 controls genotyped on the 317K chip. Second, we imputed (see below for details) the 831 Swedish controls genotyped with the 317K array to create a larger set of overlapping SNPs. Of the remaining SNPs, we captured 4,605 SNPs by imputation. A final set of 11,394 overlapping SNPs was then forwarded for analysis. We filtered the SNPs in this dataset using the same thresholds as described above. The remaining 1,250 SNPs not captured by imputation were analyzed only in the original set of Swedish samples genotyped on the 12K chip.
The 831 Swedish controls genotyped with the 317K array were imputed using MACH using Phase II HapMap CEU samples as a reference 44 . Before imputation, we applied stringent quality control checks on the 317K SNPs. A subset of 293,242 markers passing the following criteria of minor allele frequency > 1%, missing rate < 5% and Hardy-Weinberg equilibrium P > 1 × 10 −6 were included in the imputation. After imputation, SNPs with low imputation quality, that is, RSQR_HAT < 0.40 reported by MACH, were discarded. An overlapping set of 11,394 markers was then available for analysis. To take into account the uncertainty in imputation, probabilistic scores rather than genotype calls were used in the analysis.
Population stratification in replication samples. For each replication cohort, we used ancestry-informative markers to correct for possible population stratification. A subset of 5,486 uncorrelated ancestry-informative markers that passed stringent quality control criteria were used to infer the top ten principal components of genetic variation using EIGENSTRAT 45 . Outliers were removed from each sample set (defined as s.d. > 6). Specifically, we removed 27 genetic outliers from the US cohort and 45 outliers from the Swedish cohort. Some degree of population stratification along the first two eigenvectors was observed in both the US and Swedish replication collections. To correct for the case-control stratification, we used one of the following strategies: (i) we applied the correction of the Cochran-Armitage test statistic incorporated in EIGENSTRAT to the US replication dataset and to the Swedish dataset wherever genotype data were available or (ii) we used principal components as covariates in a logistic regression model in the analysis of the imputed Swedish data.
Association analysis. US data. Some inflation in the test statistics was observed after performing an uncorrected 1-degree-of-freedom allelic test for association (PLINK 43 ). To correct for population stratification in the US sample, principal component analysis (EIGENSTRAT) using 5,486 uncorrelated ancestry-informative markers was conducted. First, we removed genetic outliers (defined as s.d. > 6). Second, Cochran-Armitage trend χ 2 test statistics were calculated for each genotyped SNP in 1,129 cases and 2,991 controls followed by adjustment of the test-statistic value of each SNP in EIGENSTRAT using the first four eigenvectors. Two-tailed P values based on the test statistic for each SNP were calculated. After correction for population stratifiation, the λ gc in the US samples was 1.05.
Swedish data. To examine the Swedish cohort for hidden population stratification, we used 5,486 ancestry-informative markers genotyped in the 12K-chip samples and in additional 317K-chip controls. After removal of genetic outliers, we had 834 cases and 515 controls genotyped on the 12K chip and 823 controls genotyped on the 317K chip. We used the correction of the test statistic implemented in EIGENSTRAT on the overlapping set of 6,789 SNPs between the two arrays. To correct for stratification in the set of 4,605 SNPs genotyped in the 12K-chip samples and imputed in the 317K-chip samples, we used the first four eigenvectors determined above as covariates in a logistic regression model implemented in SNPTEST, as EIGENSTRAT was not intended for use with imputed genotype data. A small set of 1,250 markers not captured by imputation in the 317K SNPs was analyzed only in the 834 cases and 515 controls genotyped on the 12K chip. After correction for population stratification, the λ gc in the Swedish samples was 1.10.
Meta-analysis.
We used a weighted z-score method to conduct the metaanalysis. To combine results across different cohorts, alleles were oriented to the forward strand of NCBI36 reference sequence of the human genome to avoid ambiguity associated with C/G and A/T SNPs. P values for each cohort were converted to z scores taking into account direction of effect relative to an arbitrary reference allele. A weighted sum of z scores was calculated by weighing each z score by the square root of the sample size for its associated cohort and then dividing this sum by the square root of the total cohort sample size. The combined z score for the Swedish and US replication cohorts were converted to one-tailed P values. The meta-analysis z score was converted to a two-tailed P value and evidence for association was evaluated. We considered SNPs passing a threshold of P < 5 × 10 −8 as overwhelmingly associated with SLE. Loci with combined P < 1 × 10 −5 that did not pass genome-wide significance were considered strong candidates for association with SLE. The meta-analysis was carried out using the METAL software package. To calculate pooled ORs, we used the Cochran-Mantel-Haenszel method. ORs were calculated relative to the risk allele for each SNP. Also, a weighted average allele frequency in controls was calculated relative to the risk allele of each SNP.
